Composite Endpoints in Multiple Sclerosis Progression and Disability - Dr. Jerry Wolinsky

For years, multiple sclerosis researchers have been looking for a measure of MS progression and disability that would be meaningful to clinicians, clinical researchers, patients, and the regulatory agencies that approve new drugs, such as the European Medicines Agency and in the U.S., the Food and Drug Administration. To this end, people have looked to composite endpoints that are sensitive to small changes in patient condition and are comparable across studies. At the ECTRIMS congress Barcelona, I met with Dr. Jerry Wolinsky, Professor of Neurology and Director of the MS Research Group at the University of Texas Health Science Center at Houston, who leads us along the path to develop a useful measure incorporating composite endpoints.